The Kowalinski group investigates the architecture and mechanisms of macromolecular complexes involved in cellular RNA editing and modification.Edit
The group has a keen interest in gene expression regulation through RNA processing pathways. Post-transcriptional chemical RNA modifications are ubiquitous (tRNA, mRNA, rRNA, snoRNA, etc.) and occur in all kingdoms of life. For example, eukaryotic tRNAs contain on average 13 modifications per molecule that assure translation fidelity and efficiency. Modifications to mRNAs have effects on folding, solubility, transcript stability, splicing, and RNA localisation. Thus, the so-called epitranscriptome adds an additional layer of information to the message. This layer is reversible in response to cellular stress, metabolic changes, or developmental stage. But also tRNAs carry various chemical modifications. In the Kowalinski group we are investigating macromolecular complexes that modify RNA or recognise modified RNAs. We solve structures of these complexes by single-particle cryo-electron microscopy (cryo-EM) and X-ray crystallography to understand the following questions: how exactly is a specific RNA selected for modification? How is this process regulated? How does a modified RNA differ in its binding to downstream effectors?
In the future, the Kowalinski group wants to gain insight into the mechanisms that specify certain RNAs for modification and how the editing is controlled. To this end, we will not only reconstitute recombinant complexes in vitro but also purify native endogenous complexes for structural investigation. We will use X-ray crystallography, cryo-EM, and scattering techniques like small-angle X-ray scattering (SAXS), combined with biophysical methods, biochemical assays, and cell biology to assess the structure–function relationship within these complexes. RNA modifications are relevant to diseases like cancer but also play a role in infectious diseases. like trypanosomiasis and leishmaniasis. In the future we hope to be able to use our knowledge for structure-aided drug design.